JP2025516364A5 - - Google Patents

Info

Publication number
JP2025516364A5
JP2025516364A5 JP2024565317A JP2024565317A JP2025516364A5 JP 2025516364 A5 JP2025516364 A5 JP 2025516364A5 JP 2024565317 A JP2024565317 A JP 2024565317A JP 2024565317 A JP2024565317 A JP 2024565317A JP 2025516364 A5 JP2025516364 A5 JP 2025516364A5
Authority
JP
Japan
Prior art keywords
disease
syndrome
fusion protein
autoimmune
protein according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024565317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516364A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/054721 external-priority patent/WO2023214387A1/en
Publication of JP2025516364A publication Critical patent/JP2025516364A/ja
Publication of JP2025516364A5 publication Critical patent/JP2025516364A5/ja
Pending legal-status Critical Current

Links

JP2024565317A 2022-05-06 2023-05-05 新規cd200融合タンパク質 Pending JP2025516364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202206672 2022-05-06
GB2206672.4 2022-05-06
PCT/IB2023/054721 WO2023214387A1 (en) 2022-05-06 2023-05-05 Novel cd200 fusion proteins

Publications (2)

Publication Number Publication Date
JP2025516364A JP2025516364A (ja) 2025-05-27
JP2025516364A5 true JP2025516364A5 (enExample) 2026-05-14

Family

ID=86609583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024565317A Pending JP2025516364A (ja) 2022-05-06 2023-05-05 新規cd200融合タンパク質

Country Status (6)

Country Link
US (1) US20260116951A1 (enExample)
EP (1) EP4519297A1 (enExample)
JP (1) JP2025516364A (enExample)
CN (1) CN119365483A (enExample)
CA (1) CA3251037A1 (enExample)
WO (1) WO2023214387A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606217B2 (en) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JP2002541210A (ja) 1999-04-13 2002-12-03 シェーリング コーポレイション 哺乳動物ox2タンパク質および関連試薬の新規な使用
EP2121015A4 (en) 2007-01-11 2010-03-24 Boehringer Ingelheim Int CD200 AND RECEPTOR THEREFOR, CD200R AND BONE MASS MODULATION BY ESTEOKLASTENDIFFERENZIERUNG
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Similar Documents

Publication Publication Date Title
JP2025515191A5 (enExample)
US11203628B2 (en) CD200 mutants and its uses
JP2018527011A5 (enExample)
JP2015526064A5 (enExample)
CA2431600A1 (en) Molecules with extended half-lives, compositions and uses thereof
JP2024542096A5 (enExample)
EP3464347B1 (en) Cysteine-optimized stradomers
JP2019527053A5 (enExample)
RU2019100381A (ru) Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
CN111108127A (zh) 用于治疗神经变性和炎性疾病的特异性结合cd38的化合物
JP2026509975A (ja) 抗pd-1/il-2融合タンパク質、医薬組成物、及び治療応用
JP2024504366A5 (enExample)
US20260116946A1 (en) Novel cd200 fusion proteins
US20250026805A1 (en) Novel proteins
WO2025087363A1 (zh) 用TACI-Fc融合蛋白治疗自身免疫性脑炎的方法
NZ747665B2 (en) Cd200 mutant and its uses
WO2024123675A2 (en) Taci-fc fusion proteins for multifunctional inhibition of baff, april, and neonatal fc receptor
JP2022513490A5 (enExample)
US20260116951A1 (en) Novel cd200 fusion proteins
US20260083671A1 (en) Stabilized formulation comprising recombinant stabilized galectin 9 protein
JP2024524880A5 (enExample)
RU2023135361A (ru) Белки, которые связываются с cd80 и/или cd86 и ox40l
CN121152636A (zh) 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法
CA3282170A1 (en) Stabilized formulation comprising recombinant stabilized galectin 9 protein
BR122025011033A2 (pt) Composição que compreende um anticorpo anti-il-5, uso terapêutico da mesma, bem como composição farmacêutica que compreende a dita composição